BTG Has The Firepower For Its Next Steps In Interventional Med
UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.
You may also be interested in...
A PMA for the PneumRx ELEVAIR endobronchial coil system will be considered by a US FDA advisory panel in June, but there will likely be some questions about the data.
Pulmonx is almost ready to submit the results of the pivotal LIBERATE trial of its Zephyr endobronchial valve to the US FDA. The data will support a premarket approval and the company hopes to bring the device, along with the Chartis patient-selection system, to the US market in 2018.
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.